Virility Medical, an Israeli medtech startup specializing in sexual wellbeing, raised $10 million for its premature ejaculation treatment called the vPatch. The $10 million represents just the first part of a planned $40 million raise.
First, there was Viagra, the miracle pill that cured erectile dysfunction. Countless men around the world no longer needed to worry about impotence, possibly the most embarrassing medical problem for a man to have.
The second most embarrassing sexual problem would be premature ejaculation. The Mayo Clinic explains that premature ejaculation occurs in men when semen leaves the body (ejaculate) sooner than wanted during sex. Premature ejaculation is a common sexual complaint. As many as 1 out of 3 people say they have it at some time. However, premature ejaculation isn’t cause for concern if it doesn’t happen often.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
This and impotence are medical conditions. But afflicted men have been forced to endure mockery over the years as society has seen them as a sign of a lack of masculinity.
The demand for a better treatment for this condition explains why Virility Medical is having such an easy time raising new funding. It is doing so as its fellow Startup Nation firms, including unicorns, have been forced to lay off staff due to the world economic crisis.
“Such rapid securing of this investment, given current market conditions which are characterized by great uncertainty, indicates the business potential inherent in Virility,” said David Salton, CEO of Virility Medical.
Founded in 2016 by Tal Gollan, a biomedical engineer, Virility’s main product the vPATCH, an FDA-cleared, CE-marked approved, wearable skin patch, is designed to delay ejaculation. Virility says that the vPATCH is clinically proven to help you last longer, perform better, and delay ejaculation using cutting-edge muscle stimulation technology.
The vPATCH is flexible, conforms to local anatomy, and is easily positioned according to anatomical landmarks. The vPATCH has been clinically proven and its technology has been commercially used for many years.
The technology enhances men’s ability to contract the pelvic-floor muscles and postpone ejaculation by delivering transcutaneous neuromuscular stimulation.
The company received FDA approval for the Virility Patch in January.
“The Virility Patch creates a paradigm shift in sexual wellbeing, prolonging time until ejaculation and fulfilling the desire to last longer during sexual intercourse,” said Tal Gollan, founder of Virility Medical. “The patch improves a man’s time to climax, creating a better outcome for couples.”
Gollan continued, “Every physical action in the body, including ejaculation, has muscles associated with it. Our technology enhances men’s ability to contract the pelvic-floor muscles and postpone ejaculation by delivering transcutaneous neuromuscular stimulation. The core technology of the patch exists and has been used safely in consumer applications for years.”
Virility is also developing another product called the vSMART.
The vSMART is a skin patch that can be paired with Bluetooth-connected cyber secure mobile app it allows the users to personalize the intensity of stimulation and explore their sexual performance. The vSMART has already been used in clinical trials.